# Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas

> **NCT06253234** · PHASE1 · RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 12 (estimated)

## Conditions studied

- WHO Grade III Gliomas
- WHO Grade IV Gliomas

## Interventions

- **BIOLOGICAL:** personalized dendritic cell injection ZSNeo-DC1.1

## Key facts

- **NCT ID:** NCT06253234
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-02
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06253234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06253234, "Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06253234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*